mission

We protect people’s lives and health, producing the world’s best technologies which are available for everyone to everyone

About

News

28.04.2025 Evgeny Barinov takes part in the forum for leaders, CEOs, and HR directors "The New Reality of Management"

11.04.2025 The Russian Ministry of Health authorised a phase III clinical trial of a new pneumococcal vaccine

31.03.2025 Nanolek received a registration certificate for the first Russian vaccine against human papillomavirus

24.02.2025 Gennady Schweigert and Pavel Mileiko acquire 50% stake in Nanolek LLC

07.02.2025 Russian Ministry of Health Approves Clinical Studies of Varicella Vaccine

31.01.2025 Brukinsa® is Included in the List of Vital and Essential Drugs

30.01.2025 Nanolek entered the TOP-20 largest taxpayers of the Kirov region

24.01.2025 Evgeniy Barinov was appointed General Director of Nanolek

13.01.2025 Nanolek Donated New Year's Gifts to Nadezhda Children's Aid Center

Vaccines

Numbers

“Nanolek” entered Russia’s top 50 fastest growing companies

RBC rating ↗

About

18.1

billion rubles

the company's turnover in 2023

the average

annual rate of growth in 2017-2023

200

million

tablets have been produced since 2014 — enough to lay a road from Kirov to the “Vostok” Antartic station

million

children in Russia have already been immunized with vaccines produced by “Nanolek”

Plant

At the innovative Nanolek Plant in the Kirov region medicines are produced according to international GMP* standards

Drugs for the treatment of cancer

Bavencio

Avelumab — Human Immunoglobulin Gl, Monoclonal antibody

Brukinza

Zanubrutinib is a selective low—molecular-weight inhibitor of Bruton tyrosine kinase, an oncohematological drug

Darzalex

Daratumumab is a monoclonal antibody that acts on the CD38 surface protein

Lomustine

Lomustin is an antitumor drug of alkylating action

Neupomax

Filgrastim — recombinant human granulocyte colony stimulating factor

Stibevara

Bevacizumab is a recombinant hyperchymeric monoclonal IgG1 antibody

Tretinoin

Drugs for the treatment of orphan diseases

Hunterase

Iduronate-2-sulfatase is a drug for enzyme replacement therapy for Hunter syndrome

R&D

The own R&D center of Nanolek was opened in 2021 in the science city of Pushchino. In 2024, a Scientific and Practical Center for Pharmaceutical Development was established on its premises within the territory of the BMC. Here, new vaccines are created from scratch, starting from the development of the active substance to conducting preclinical and clinical trials, followed by scaling up for production.

The path of a drug from a molecule to market entry takes up to 6 years. Early development of development of a single molecule takes 1-2 years. Furthermore, on average only 10 out of 100 hypotheses of molecules make it to market.

The Scientific and Practical Center will occupy an area of 300 m2 and will be equipped with all necessary facilities for the development and production of vaccines, including high-tech laboratory and pilot installations for obtaining experimental and pilot-industrial batches of vaccine antigens.